ARID1A and neoplasm: A second extension could include synthetic lethal interactions with PARP and ATR inhibitors beyond BRCA loss and HRD, such as ARID1A [55, 56] and ATM mutations [10, 29, 57], which would further help identify tumours most likely to respond to specific treatments.